A lawsuit has been filed against Pfizer relating to Depo-Provera, formally known as depot medroxyprogesterone acetate, a progesterone-based birth control injection you receive once every three months. The lead plaintiff, Robin Phillip, who used the shot for nearly 30 years, is a survivor of intracranial meningioma—a tumor in the lining of the brain. Phillip only stopped using the shot during her two pregnancies and believed that her symptoms were signs of a more serious issue. Although emergency surgery was successful, she lost vision in her left eye and faced a long recovery.
In her claim, along with 1,000 other co-plaintiffs, she states that Pfizer knew about the medication’s effects and risks, but failed to warn its patients. Nonetheless, Pfizer submitted a motion to dismiss the case and reaffirmed its confidence in the medication despite the allegations.
Recent studies have confirmed that meningiomas are usually not cancerous. However, there are patients who received Depo-Provera that had a higher risk of meningioma, especially with prolonged use and at older ages. Although this area is still under ongoing research, it is known that women are more likely to develop this type of brain tumor by age 50. Additionally, some findings suggest that after using the Depo Shot, pregnancy and menopausal hormone therapy may speed up meningioma growth.
Although 1 in 4 sexually active women use the Depo injection nationally, Black women use nearly double. This makes Black women even more predisposed to the risk of meningioma in the United States. It has already been proven that Black women are 41% more likely to develop cervical cancer.
Furthermore, Black women are more likely to be diagnosed with HPV, which often serves as a preliminary diagnosis that can lead to other forms of cancer. Black women are also among the most affected by medical racism and discrimination within the healthcare system. Although the risks of this medication are not taken seriously, it is crucial to recognize how much this medication impacts its largest patient demographic.
Although the FDA has declined to reevaluate these concerns at this time, other countries have issued warnings about the risks associated with Depo, including European agencies, South Africa, and Canada. This indicates that there is a serious concern with the risks. While the case is not yet fully resolved, the survivors’ testimonies suggest that the FDA and Pfizer may need to evaluate the risks of this medication and consider how to alert consumers.

